SCLC ClinicalImpact: New Tools and Expert Guidance for Integrating Immunotherapies

Download All
Get expert insights on the optimal integration of immunotherapies in the treatment of small-cell lung cancer with expert-authored commentaries, a series of 10 brief interactive videos with downloadable slidesets, and a new Interactive Decision Support Tool with expert recommendations individualized to your specific patient scenarios.
Anne Chiang, MD, PhD
Nicolas Girard, MD, PhD
person default
Benjamin Levy, MD
Taofeek K. Owonikoko, MD, PhD
Mark A. Socinski, MD
Lauren A. Byers, MD
Anne Chiang, MD, PhD
Christine L. Hann, MD, PhD
Stephen V. Liu, MD
Thomas Stinchcombe, MD

ClinicalThought

Read my thoughts on the importance of using combination chemoimmunotherapy as first-line treatment for extensive-stage SCLC.

Taofeek K. Owonikoko, MD, PhD Released: October 13, 2020

Do you know about the key clinical trials in relapsed extensive-stage small-cell lung cancer presented at WCLC 2020?

Nicolas Girard, MD, PhD Released: March 1, 2021

Read this expert commentary for an overview of our new treatment decision support tool for extensive-stage small-cell lung cancer, which provides treatment recommendations from 5 lung cancer experts for your patients with newly diagnosed and relapsed/refractory disease.

Anne Chiang, MD, PhD Released: May 26, 2021

Video Modules

Review key data that support use of concurrent chemoradiotherapy with cisplatin plus etoposide as standard of care for LS-SCLC.

person default Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

Gain expert insight on the biologic rationale for using immune checkpoint inhibition for the treatment of ES-SCLC, including the potential for synergism between immunotherapy and platinum-based chemotherapy.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short video evaluating key clinical trial data supporting use of first-line immune checkpoint inhibitors plus chemotherapy in the treatment of newly diagnosed ES-SCLC.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short video discussing current best practices for treating a patient with newly diagnosed extensive-stage SCLC.

person default Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 9, 2020 Expired: December 8, 2021

View this short video evaluating the clinical trial data for second-line and third-line treatment options for relapsed ES-SCLC.

person default Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Watch this short case-based video for an overview of the evolving systemic therapy options for the treatment of relapsed ES-SCLC.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 5, 2021 Expired: February 4, 2022

Watch this short video on early recognition and management of immune-related adverse events from immunotherapy for the treatment of ES-SCLC in the context of a patient case.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 5, 2021 Expired: February 4, 2022

Watch this short video to get up to date on the role of prophylactic cranial irradiation and consolidative thoracic radiotherapy in the treatment of ES-SCLC.

person default Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 2, 2021 Expired: February 1, 2022

Watch this short video to get up to date on the role of biomarkers in predicting benefit of immune checkpoint blockade during treatment of extensive-stage SCLC.

person default Benjamin Levy, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 1, 2021 Expired: January 31, 2022

Watch this short video for an expert review of key ongoing trials of immune checkpoint inhibitor combinations for SCLC to consider for your patients, including ADRIATIC and NRG-LU005 for limited-stage disease and SKYSCRAPER-02 for extensive-stage disease.

Mark A. Socinski, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 2, 2021 Expired: February 1, 2022

Interactive Decision Support Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with ES-SCLC with those of 5 renowned lung cancer experts.

Lauren A. Byers, MD Anne Chiang, MD, PhD Christine L. Hann, MD, PhD Stephen V. Liu, MD Thomas Stinchcombe, MD Released: May 24, 2021

Downloadable Slidesets

Download this brief slideset on best practices for treating LS-SCLC.

person default Benjamin Levy, MD Released: December 1, 2020

Download this brief slideset on the rationale for using immunotherapy in the treatment of ES-SCLC.

Mark A. Socinski, MD Released: December 1, 2020

Download this brief slideset for a review of the latest clinical data informing optimal use of immunotherapy for treatment-naive ES-SCLC.

Mark A. Socinski, MD Released: December 1, 2020

Download this brief slideset featuring a case presentation of a patient with newly diagnosed extensive-stage SCLC.

person default Benjamin Levy, MD Released: December 9, 2020

Download this brief slideset for a review of the latest clinical data informing optimal treatment of relapsed ES-SCLC.

person default Benjamin Levy, MD Released: December 1, 2020

Download this brief slideset featuring a case presentation of a patient with relapsed extensive-stage SCLC.

Mark A. Socinski, MD Released: February 5, 2021

Download this brief slideset featuring a case presentation of a patient with ES-SCLC who developed an immune-related adverse event while being treated with immunotherapy.

Mark A. Socinski, MD Released: February 5, 2021

Download this brief slideset to review the available clinical data informing optimal use of radiotherapy in treating patients with ES-SCLC.

person default Benjamin Levy, MD Released: February 2, 2021

Download this brief slideset for an update on biomarkers to guide treatment of patients with ES-SCLC with immunotherapy.

person default Benjamin Levy, MD Released: February 1, 2021

Download this brief slideset featuring select ongoing clinical trials of immunotherapy for the treatment of SCLC.

Mark A. Socinski, MD Released: February 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue